These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22208035)

  • 1. [Androgen synthesis inhibitors and new androgen receptor antagonists].
    Nishiyama T
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():511-5. PubMed ID: 22208035
    [No Abstract]   [Full Text] [Related]  

  • 2. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
    Bedoya DJ; Mitsiades N
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer: The androgen receptor remains front and centre.
    Saylor PJ
    Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000
    [No Abstract]   [Full Text] [Related]  

  • 4. [New inhibitors of adrenal androgen synthesis enzymes].
    Mizokami A
    Nihon Rinsho; 2014 Dec; 72(12):2158-63. PubMed ID: 25518351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Boissier E; Loriot Y; Vignot S; Massard C
    Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].
    Audenet F; Murez T; Ripert T; Villers A; Neuzillet Y
    Prog Urol; 2013 Oct; 23 Suppl 1():S9-15. PubMed ID: 24314739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
    Njar VC; Brodie AM
    J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor.
    Bryce A; Ryan CJ
    Clin Pharmacol Ther; 2012 Jan; 91(1):101-8. PubMed ID: 22130117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
    Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
    Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.
    Bjartell A
    Eur Urol; 2011 Nov; 60(5):905-7. PubMed ID: 21871707
    [No Abstract]   [Full Text] [Related]  

  • 12. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
    Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
    Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone acetate: a hat trick of clinical benefits.
    Schweizer MT; Antonarakis ES
    Lancet Oncol; 2012 Dec; 13(12):1173-4. PubMed ID: 23142060
    [No Abstract]   [Full Text] [Related]  

  • 16. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
    Gianti E; Zauhar RJ
    J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drug treatment possibilities in castration resistant prostate carcinoma].
    Meisel A; Stenner F
    Praxis (Bern 1994); 2012 Sep; 101(18):1143-9; quiz 1150-1. PubMed ID: 22945814
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibitors of enzymes of androgen biosynthesis: cytochrome P450(17) alpha and 5 alpha-steroid reductase.
    Jarman M; Smith HJ; Nicholls PJ; Simons C
    Nat Prod Rep; 1998 Oct; 15(5):495-512. PubMed ID: 9807812
    [No Abstract]   [Full Text] [Related]  

  • 19. [Research and development of hormone-related anti-prostate cancer drugs-17, 20-lyase inhibitors for prostate cancer].
    Hara T
    Nihon Yakurigaku Zasshi; 2010 Oct; 136(4):192-7. PubMed ID: 20948153
    [No Abstract]   [Full Text] [Related]  

  • 20. [Abiraterone acetate(ZYTIGA®)-development and literature review].
    Nishimura Y; Mukai H; Suzukawa K; Oyama R
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):811-6. PubMed ID: 25131865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.